CBD Drugs

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) beat the consensus estimate for its fourth-quarter loss Monday and provided some highlights from its ongoing and upcoming trials. What Happened The company posted revenue of just $86,000 for the quarter ended Dec. 31, which was the only revenue...